Brandon Becker
Overview
Explore the profile of Brandon Becker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Armstrong A, Augustin M, Beaumont J, Pham T, Hudgens S, Gordon K, et al.
Dermatol Ther (Heidelb)
. 2025 Mar;
PMID: 40048065
No abstract available.
2.
Tada Y, Armstrong A, Imafuku S, Okubo Y, Morita A, Zhong Y, et al.
J Dermatol
. 2024 Dec;
52(2):353-358.
PMID: 39641509
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in Japan for adult patients with plaque, generalized pustular, or erythrodermic psoriasis. POETYK PSO-4 (NCT03924427), an open-label, single-arm, phase...
3.
Patel V, Park S, Zhong Y, Sima A, Zhuo J, Roberts-Toler C, et al.
Psoriasis (Auckl)
. 2024 Dec;
14:167-174.
PMID: 39624651
Purpose: This real-world study investigated the impact of patient-reported disease burden and health-related quality of life (HRQoL) on switching from systemic nonbiologic to biologic therapy in patients with plaque psoriasis....
4.
Barsdorf A, Fastenau J, Lee S, Li X, OBrien E, Stevenson B, et al.
Qual Life Res
. 2024 Nov;
34(1):101-111.
PMID: 39576501
Purpose: Thrombotic cardiovascular diseases profoundly impact patients' health-related quality of life (HRQoL). However, patient-reported outcome (PRO) instruments that are disease-specific or antithrombotic-treatment focused, developed according to US Food and Drug...
5.
Armstrong A, Augustin M, Beaumont J, Pham T, Hudgens S, Gordon K, et al.
Dermatol Ther (Heidelb)
. 2024 Jul;
14(8):2235-2248.
PMID: 39080153
Introduction: Deucravacitinib, a novel, oral, selective allosteric tyrosine kinase 2 inhibitor, demonstrated superiority versus placebo and apremilast in the POETYK PSO-1 and PSO-2 studies. We describe patient-reported outcomes with deucravacitinib...
6.
Strand V, Gossec L, Coates L, Ogdie A, Choi J, Becker B, et al.
Arthritis Care Res (Hoboken)
. 2024 Mar;
76(8):1139-1148.
PMID: 38529674
Objective: Deucravacitinib, a tyrosine kinase 2 inhibitor, was assessed in a phase 2 trial in patients with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from the patient...
7.
Buckley C, Simon-Campos J, Zhdan V, Becker B, Davy K, Fisheleva E, et al.
Lancet Rheumatol
. 2024 Jan;
2(11):e677-e688.
PMID: 38279364
Background: The human monoclonal antibody otilimab inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF), a key driver in immune-mediated inflammatory conditions. We aimed to evaluate the efficacy, safety, and key patient-reported outcomes related...
8.
Papp K, Gordon K, Strober B, Zhuo J, Becker B, Zhong Y, et al.
JAMA Dermatol
. 2023 Dec;
160(2):204-209.
PMID: 38117487
Importance: Change from baseline score on the validated Psoriasis Symptoms and Signs Diary (PSSD) is a widely used, patient-reported end point in clinical trials for psoriasis. Meaningful score change thresholds...
9.
Becker B, Bracher M, Chauhan D, Rendas-Baum R, Lin X, Raymond K, et al.
J Patient Rep Outcomes
. 2021 Dec;
5(1):129.
PMID: 34894330
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disease often associated with persistent pain. There is a need for a patient-reported outcome measure (PROM) that is rooted in the patient...
10.
Sully K, Bonner N, Bradley H, von Maltzahn R, Arbuckle R, Walker-Nthenda L, et al.
J Patient Rep Outcomes
. 2021 Nov;
5(1):118.
PMID: 34743264
Background: Accurate symptom monitoring is vital when managing pediatric asthma, providing an opportunity to improve control and relieve associated burden. The CHILDHOOD ASTHMA CONTROL TEST (C-ACT) has been validated for...